Cramer Likes Azek And SoFi, But Said Owning This Stock Could Be Dreadful
On CNBC's "Mad Money Lightning Round," Jim Cramer said MyMD Pharmaceuticals Inc (NASDAQ: MYMD) is very speculative and one needs to be gutsy to buy it.
Weyerhaeuser Distribution Expands AZEK Portfolio To Texas Market
The AZEK® Company (NYSE:AZEK) and Weyerhaeuser Company (NYSE:WY) today announced an expansion of Weyerhaeuser's product portfolio with AZEK Building Products, a wholly owned subsidiary of The AZEK
RBC Capital Maintains Outperform on AZEK Co, Raises Price Target to $54
RBC Capital analyst Mike Dahl maintains AZEK Co (NYSE:AZEK) with a Outperform and raises the price target from $52 to $54.
Azek Stock Gains On Strong Q3, Raised FY21 Sales Outlook
Azek Company Inc (NYSE:AZEK) reported third-quarter sales growth of 46.4% year-over-year to $327.45 million, beating the consensus of $291.53 million. Sales…
AZEK Co Q3 EPS $0.26 Beats $0.23 Estimate, Sales $327.50M Beat $291.53M Estimate
AZEK Co (NYSE:AZEK) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.23 by 13.04 percent. This is a 100 percent increase over earnings of $0.13 per share from the same period
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
Looking Into AZEK Co’s Return On Capital Employed
Looking at Q2, AZEK Co (NYSE:AZEK) earned $36.82 million, a 84.57% increase from the preceding quarter. AZEK Co also posted a total of $293.12 million in sales, a 38.08% increase since Q1. In Q1, AZEK Co earned $19.95 million, and total sales reached $212.28 million.
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell
• CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.